Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Arte... ( MOBILITY trial showcases company's le...)

Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease

Date:4/1/2009

MOBILITY trial showcases company's leadership in developing innovative endovascular treatment options

ABBOTT PARK, Ill., April 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the initiation of MOBILITY, a clinical trial studying the safety and efficacy of the Absolute Pro(TM) Peripheral Self-Expanding Stent System in patients with iliac artery disease. Iliac artery disease is a form of peripheral artery disease (PAD) that affects the lower extremities. The first patient was enrolled into the MOBILITY trial by John Campbell, M.D., assistant professor of surgery and medicine, West Virginia University School of Medicine, Charleston Division, at the Charleston Area Medical Center in Charleston, W. Va.

"Iliac artery occlusive disease has the potential not only to have a significant impact on a patient's ability to carry on daily activities, but it also can be an early sign of plaque buildup in other parts of the body," said Manish Mehta, M.D., M.P.H., FACS, director of Endovascular Services, The Vascular Institute for Health and Disease, Albany Medical Center in Albany, N.Y., and co-principal investigator of the MOBILITY trial. "The lower extremity discomfort and fatigue with walking and exercise caused by this debilitating disease can tremendously impact a patient's overall quality of life, making it critical to find effective treatments. Data from the MOBILITY trial will be an important addition to iliac stenting research."

PAD affects approximately 8 million people in the United States,* and occurs when the blood vessels in the legs become blocked or narrowed by plaque, reducing blood flow to the limbs. The most common symptom of PAD is claudication, a sharp, cramp-like pain in the legs that occurs when walking or exercising. For patients with iliac a
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Abbott Hosts Conference Call for First-Quarter Earnings
2. Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
3. Abbott to Present at Cowen Annual Health Care Conference
4. Abbott Announces Required Offer to Repurchase Convertible Senior Subordinated Notes of Its AMO Subsidiary
5. Abbott Completes Acquisition of Advanced Medical Optics
6. Abbott Opens New Pediatric Nutrition Manufacturing Facility in Singapore
7. Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
8. Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
9. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
10. Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
11. Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbotts Architect(R) Analyzers

Post Your Comments:

Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Arte...( MOBILITY trial showcases company's le...),Health